Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment Table 2 Disease activity before/after tofacitinib plus IGU treatment
No. Case 1 Case 1 Case 2 Case 2 Case 2 Case 2 Case 3 Case 3 Case 3
Index Base line Follow up 1 Base line Follow up 1 Follow up 2 Follow up 3 Base line Follow up 1 Follow up 2
RBC(×1012L) 3.89 4.63 3.64 3.19 3.29 3.36 3.84 4.09 3.92
HGB(g/l) 99 130 106 103 105 104 111 126 121
WBC(×109/L) 6.8 5.8 4.84 5.34 5.78 6.32 7.73 11.7 10.9
PLT(×109/L) 260 269 289 263 235 243 309 367 363
ANA (-) 1:100 1:3200 1:3200 1:3200 1:3200 1:100 1:100 1:100
RF(<20IU/ml) 139.9 40 55.5 26.4 22.3 38.9 211 99 39
CCP(<5RU/ml) >200 112.5 >200 165.8 158.6 148.2 149 102 159.8
AKA (-) (-) (-) (-) (-) (-) (-) (-) (-)
APF (-) (-) (+) (±) (±) + + + +
CRP(<10mg/L) 30.3 1.6 12.5 <3.13 2.68 12.4 18.2 2.8 8.08
ESR(<15mm/h) 56 36 54 32 31 30 44 31 41
IgG(<16g/l) 13.7 12.3 19.1 14.6 13.7 18 16.2 14.3 11.9
NO. of Swollen Joints 9 2 8 2 6 4 11 1 1
NO. of Tenderness Joints 10 3 10 2 8 7 14 3 2
DAS28-CRP 5.49 2.02 4.77 2.22 3.25 4.1 5.26 1.6 2.2
PGA 7 1.3 5 1.5 2.3 5 6 1 1.5
TLC-SB 88.2 91.3 85.9 80.1 81.2 78.1 83 76.2 74.2
FVC% 85.2 95.9 112.9 113.2 109.8 94.6 75.8 71.7 72.9
FEV1% 76.4 88.10 115 109 109.7 108.4 111.1 117.5 122.8
DLCO SB% 70.1 75.7 102.4 79.2 85.1 66.5 84.1 81.1 79.3
Total GGO score 6 5 9 6 7 7 8 5 5
Total fibrosis score 7 5 10 8 11 11 12 5 5